The impact of glucocorticoid use on the outcomes of rheumatoid arthritis in a multicenter ultrasound cohort study

• Published in: International journal of rheumatic diseases 2024-03, Vol.27 (3), p.e15118-n/a
• Main Authors: Nonaka, Fumiaki, Fukui, Shoichi, Michitsuji, Tohru, Endo, Yushiro, Nishino, Ayako, Shimizu, Toshimasa, Umeda, Masataka, Sumiyoshi, Remi, Koga, Tomohiro, Iwamoto, Naoki, Origuchi, Tomoki, Ueki, Yukitaka, Eiraku, Nobutaka, Suzuki, Takahisa, Okada, Akitomo, Matsuoka, Naoki, Takaoka, Hirokazu, Hamada, Hiroaki, Tsuru, Tomomi, Arinobu, Yojiro, Hidaka, Toshihiko, Fujikawa, Keita, Yoshitama, Tamami, Tada, Yoshifumi, Ohtsubo, Hideo, Ishizaki, Jun, Asano, Tomoyuki, Maeda, Takahiro, Kawakami, Atsushi, Kawashiri, Shin‐ya
• Format: Article
• Language: English
• Subjects: Cohort analysis; glucocorticoid; Glucocorticoids; grayscale; Methotrexate; Patients; power Doppler; Prednisolone; remission; Rheumatoid arthritis; Ultrasonic imaging; Ultrasound
• ISSN: 1756-1841; 1756-185X
• DOI: 10.1111/1756-185X.15118

Objective Glucocorticoids are effective in treating rheumatoid arthritis (RA) when used appropriately considering the balance of the risks and benefits, especially at low doses. We aimed to evaluate the response of biologic and targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) in patients having already been treated with glucocorticoids. Methods We reviewed RA patients treated with b/tsDMARDs in a prospective multicenter ultrasound cohort study. We compared the differences in the clinical characteristics at baseline and outcomes at 12 months between the two groups having been treated with and without glucocorticoids at baseline. The differences in the clinical characteristics and the treatments were balanced by the inverse probability weighting (IPW) with the propensity score. Results Of 307 patients with RA, 160 patients were treated with glucocorticoids at baseline. The median dose of glucocorticoids was equivalent to 5.0 mg/day of prednisolone. Significant differences were in age and concomitant methotrexate use, composite measures for the disease activity, and the ultrasound grayscale score at baseline. Patients treated with glucocorticoids had less frequent remissions defined by composite measures and ultrasound findings than those treated without glucocorticoids. These significant differences in the achievement of remissions remained robust even after adjusting differences in the clinical characteristics and the treatments between the two groups by IPW. Conclusion RA patients treated with glucocorticoids had a higher disease activity at baseline and a poorer response to treatments with b/tsDMARDs than those without glucocorticoids. The states of patients requiring glucocorticoids might be associated with the poor response to the b/tsDMARDs.